Products
HemaSeq Human 363 Gene Mutation Detection Kit （NGS-for Illumina）
Cat. No.:
S0910-S
Spec:
6 rxns/Kit（60 Tests）
Product description
Parameters
Detection Content
NGS technology enables the detection of mutations in 363 gene at once involving various signaling pathways of B-cell and T-cell lymphoma pathogenesis, which aids disease diagnosis, differential diagnosis, prognosis, and treatment.
Advantages
1. Covers related genes on various signaling pathways of pathogenesis and key genes in WHO, NCCN, guidelines of Chinese Society of Clinical Oncology (CSCO) lymphoid malignancies, Chinese guidelines for diagnosis and treatment of lymphoma subtypes, expert consensuses and authoritative literature to assist clinical decision-making and meet scientific research needs.
2. Covers library preparation reagents, hybrid capture reagents, and probes for 363 genes in Kit components (including complete exonic regions of all genes).
3. Flexible with Illumina and ThermoFisher sequencing platforms.
4. High sensitivity, with accurate and stable detection of 1% mutation frequency.
Target Population
1、Solid tumors
(1) For paraffin sections, the size should preferably be ≥ 2 cm2 with a thickness of 5–6 μm; the tissue content should preferably be ≥ 50%, and the number of sections should be 5–6.
(2) For paraffin rolls, at least 8–10 paraffin rolls with a thickness of 4 μm, or 6 paraffin rolls with a thickness of 6 μm are required.
(3) For fresh tissues, the size should be at least 1 cm3. After freezing, they should be transported in dry ice to ensure a frozen status upon arrival at the laboratory, or sent to the laboratory within 7 days after being completely soaked in formalin, and then processed for paraffin sectioning. Tumor percentage should be > 20% for all types of solid tumor samples.
2、Bone marrow/Peripheral blood
2–3 mL bone marrow or peripheral blood (bone marrow preferred), with > 5% tumor cells infiltrating into the blood, and WBC count > 5*109/L; otherwise, increase sample volume (> 5 mL) when insufficient.
3、DNA
The total DNA amount should be > 1 μg, OD260/280 should be within 1.8–2.0, with a concentration > 30 ng/μL, and the agarose gel electrophoresis band should be > 20 kb.
4、Cell lines
WBC count > 15*106; total amount of extractable DNA > 1 μg.
Target Population
To meet the clinical needs of lymphoma detection, a 363-gene mutation detection panel has been designed specifically for clinical use, in accordance with the NCCN guidelines, WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (2008 and 2016 revisions), guidelines of the Chinese Society of Clinical Oncology (CSCO) for lymphoid malignancies, Chinese guidelines for diagnosis and treatment of lymphoma subtypes, expert consensuses, authoritative classics, and the latest literature. This panel is applicable to patients with DLBCL, FL, BL, MCL, MZL, HCL, WM, AITL (newly named as nTFHL-AI by WHO 2022 Classification), LGLL, ALCL, HL and other common lymphomas.
Gene List (only partial genes displayed)
|
ABL2 |
ARID1B |
ATG5 |
BACH2 |
BRCA1 |
CBFA2T3 |
|
ACTB |
ARID2 |
ATM |
BCL10 |
BTG1 |
CBLB |
|
ACTG1 |
ARID3A |
ATP1A1 |
BCL11A |
BTG2 |
WISP3 |
|
AKT1 |
ARID3C |
ATP2B3 |
BCL2 |
BTK |
CCNB1IP1 |
|
AKT3 |
ARID4B |
ATP6AP1 |
BCL6 |
BTLA |
CCND1 |
|
ANKRD11 |
ARID5A |
ATP6V1B2 |
BCL7A |
BUB1B |
CCND2 |
|
APC |
ARID5B |
ATR |
BCOR |
CAD |
CCND3 |
|
APH1A |
ARNT |
ATRX |
BCR |
CAMTA1 |
FAM58A |
|
APOBEC3B |
ASXL1 |
AXIN1 |
BIRC3 |
CARD11 |
CD22 |
|
ARID1A |
ASXL2 |
B2M |
BRAF |
CARM1 |
CD36 |
Ordering Information
| Cat. No. | Product | Strength |
| S0910-S | HemaSeq Human 363 Gene Mutation Detection Kit （NGS-for Illumina） |
6 rxns/Kit （60 Tests） |
Scan the QR code to read on your phone
